Preoperative Therapy in HR+/HER2+ Early Breast Cancer: WSG-TP-II Trial Results
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
On May 11, 2023, Oleg Gluz and colleagues from the West German Study Group published the results of the WSG-TP-II clinical trial in JAMA Oncology. The study focused on patients with hormone receptor-positive (HR+) and HER2-positive early breast cancer, comparing two different neoadjuvant (pre-operative) treatment strategies.
Study Design: WSG-TP-II Trial
This prospective, randomized trial enrolled 207 patients who were randomized to receive:
- Chemotherapy Arm (N=107): Paclitaxel + Trastuzumab (Herceptin) + Pertuzumab (Perjeta).
- Endocrine Arm (N=100): Endocrine Therapy (ET) + Trastuzumab + Pertuzumab.
The primary endpoint was the pathological complete response (pCR) rate, defined as the disappearance of invasive cancer in the breast and lymph nodes at the time of surgery.
Key Efficacy Results
The chemotherapy-based regimen demonstrated significantly higher response rates:
- pCR Rate (Chemotherapy Arm): 56.4%
- pCR Rate (Endocrine Arm): 23.7%
The trial confirmed that the addition of chemotherapy (Paclitaxel) to dual HER2-targeted therapy resulted in a significantly higher likelihood of achieving pCR compared to an endocrine-based approach in this specific patient population.
Patient Characteristics
The median age of participants was 53 years. Approximately 58% of patients had tumors classified as cT2–cT4, and 28% had lymph node involvement (cN+).
Conclusion
The researchers concluded that for HR+/HER2+ early breast cancer patients, de-escalating neoadjuvant therapy to an endocrine-only approach (even with dual HER2 blockade) resulted in substantially lower pCR rates than the chemotherapy-containing regimen. These findings emphasize the continued importance of taxane-based chemotherapy in achieving optimal pathological responses in this setting.
Source: JAMA Oncology - WSG-TP-II Trial Results
#BreastCancer #HER2Positive #HRPositive #NeoadjuvantTherapy #Paclitaxel #Trastuzumab #Pertuzumab #CancerResearch
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4